lundi 4 mai 2020

Onco Actu du 4 mai 2020


1. BIOLOGIE



Understanding the diversity of cancer evolution based on computational simulation [University of Tokyo]











Researchers Find New Insights Linking Cell Division to Cancer [Huntsman Cancer Institute]











4.10 DÉP., DIAG. & PRONO. - FDA, EMA, NICE,...



EMA recommendations on DPD testing prior to treatment with fluorouracil, capecitabine, tegafur and flucytosine [EMA]










4.2 DÉP., DIAG. & PRONO. - GÉNOME



Treatment Clues Gleaned From Molecular Features in Rare Kidney Cancer Type [Genome Web]











New MDS Subtype Proposed Based on Presence of Genetic Mutation [ASH]











4.9 DÉP., DIAG. & PRONO. - SEIN



Researchers Identify Molecular Markers That May Help Predict Disease Recurrence Risk For Triple-Negative Breast Cancer Patients [Johns Hopkins]











5.1 TRAITEMENTS - PRÉ-CLINIQUE



Schizophrenia drug combined with radiation shows promise in treating deadly brain tumors [UCLA]











New targets for childhood brain tumors identified [WUSTL]











5.10 TRAITEMENTS - ESSAIS



Breast and ovarian cancer drug effective in advanced prostate cancer [Cancer Research UK]











5.12.11 IMMUNOTHÉRAPIES - PRÉ-CLINIQUE



Improving immunotherapy for cancer [Technical University of Munich]











5.12.4 IMMUNOTHÉRAPIES - ESSAIS



Novel Immunotherapy/Targeted Therapy Combination Extended Survival in Some Patients With Lethal Biliary Tract Cancers [Johns Hopkins]











5.2.5 PHARMA - BMS



Bristol Myers Squibb gets priority review for AML drug as list of potential Celgene hits lengthens [EndPoints]











U.S. Food and Drug Administration (FDA) Accepts for Priority Review Bristol Myers Squibb’s Application for CC-486 for Maintenance Treatment of Adult Patients in Remission with Acute Myeloid Leukemia [BMS]











Bristol Myers' leukemia hopeful snags speedy FDA review [Fierce Biotech]











5.3.4 TRAITEMENTS - AMM (FDA, EMA,...)



FDA approves niraparib for first-line maintenance of advanced ovarian cancer [FDA]











Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 28-30 April 2020 [EMA]











FDA approves daratumumab and hyaluronidase-fihj for multiple myeloma [FDA]










Genmab Announces U.S. FDA Approval of Subcutaneous Formulation of Daratumumab, DARZALEX FASPRO™ (daratumumab and hyaluronidase-fihj), for the Treatment of Patients with Multiple Myeloma [Genmab]











5.4 TRAITEMENTS - ECONOMIE



High Cost of Cancer Drugs Not Always Justified [University of Zurich]










5.5 ASCO



ASCO Announces Top Studies to Be Presented During Virtual Cancer Science Meeting, May 29-31 [ASCO]











5.9.12 AACR - BIOPSIES LIQUIDES



AACR Virtual Annual Meeting I: Two Liquid Biopsy Tests Offer Promise of Early Detection of Cancer [Cancer Research Catalyst]











New TraceRx Data Adds Evidence for Adjuvant Liquid Biopsy Minimal Residual Disease Testing [Genome Web]











5.9.9 AACR - IMMUNOTHÉRAPIES



AACR Virtual Annual Meeting I: Results Presented Provide Basis for FDA Decision to Approve Alternative Pembrolizumab Dosing Schedule [Cancer Research UK











6.15 LUTTE CONTRE LES CANCERS - COVID-19



Covid-19 has put cancer patients and research at huge risk [Cancer Research UK]











Deaths in people with cancer could rise by at least 20% [UCL]











Helping Cancer Survivors Cope with Cancer-Related Anxiety and Distress [NCI]











Cancer Patients Face High Mortality from COVID-19 [Albert Einstein College of Medicine]